Merck Rumored to Eye MoonLake’s MLTX After 2025 Approach as MLTX Stock Jumps 2.5%
MRK•Merck is linked to a potential acquisition of MoonLake Immunotherapeutics after a 2025 buyout approach, as MLTX stock surged 2.5% ahead of late-stage sonelokimab trial catalysts. Full 52-week hidradenitis suppurativa results are expected in Q2, adolescent HS data this year, and a September BLA aims for priority review by November.
1. Merck Potential Acquisition Interest
Merck has surfaced as a potential bidder for MoonLake Immunotherapeutics following a reported 2025 buyout approach, fueling increased M&A chatter around the biotech’s inflammatory‐disease pipeline.
2. Late-Stage Sonelokimab Trial Catalysts
MoonLake’s two Phase III trials enrolled roughly 838 patients with moderate-to-severe hidradenitis suppurativa, producing mixed week-16 topline outcomes. Investors now await full 52-week efficacy and safety data in Q2 and adolescent trial results later this year.
3. Regulatory and Approval Timeline
After a positive FDA meeting, MoonLake plans to submit a BLA in September 2026 seeking priority review by November. If accepted, the company targets a potential U.S. launch of sonelokimab in H2 2027.
